- Advanced search
- Guide to IMMUNOPHARMACOLOGY Portal
|Ligand families/groups||Immune checkpoint modulators|
|Approved drug?||Yes (FDA (2014), EMA (2015))|
|International Nonproprietary Names|
|Keytruda® | lambrolizumab | MK-3475|
|Pembrolizumab is the first-in-class, anti-PD-1 antibody to be approved by the US FDA.
Full peptide sequence and disulphide bond information is available from the IMGT/mAb-DB entry for this antibody.
Pembrolizumab is the first immuno-oncology therapeutic to be approved for use in cancers of any tissue type, so long as they express a specific genetic biomarker (i.e. high microsatellite instability (MSI-H) or mismatch repair deficient (dMMR) tumours). This is an important breakthrough, since up until this point FDA approvals, including earlier approvals for pembrolizumab, had always been restricted to certain tissue-specific cancers.
|GtoPdb PubChem SID||187051801|
|Search PubMed clinical trials||pembrolizumab|
|Search PubMed titles||pembrolizumab|
|Search PubMed titles/abstracts||pembrolizumab|